Search results

31 results for template

Sorted by Date . Sort by Relevance

  1. Tuberculosis (NG33)

    This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.

  2. Medicines optimisation in chronic pain (KTT21)

    This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  3. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  4. Developing NICE guidelines: the manual (PMG20)

    Developing NICE guidelines: the manual

  5. Biosimilar medicines (KTT15)

    The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .

  6. Medical technologies evaluation programme process guide (PMG34)

    Medical technologies evaluation programme process guide

  7. User guide for the cost comparison company evidence submission template (PMG32)

    User guide for the cost comparison company evidence submission template

  8. Single technology appraisal: User guide for company evidence submission template (PMG24)

    Single technology appraisal: User guide for company evidence submission template

  9. Evidence summaries: new medicines – Integrated process statement (PMG11)

    Evidence summaries: new medicines – Integrated process statement

  10. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    Evidence summaries: unlicensed and off-label medicines – Integrated process statement

  11. Irreversible electroporation for treating prostate cancer (IPG572)

    Evidence-based recommendations on electroporation (electrical pulses sent through a needle into a tumour) for treating prostate cancer in adults

  12. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

  13. Diabetes in adults (QS6)

    This quality standard covers care and treatment for adults with diabetes. It includes preventing type 2 diabetes, managing type 1 and type 2 diabetes, diabetes-related foot care and diabetes education programmes. It describes high-quality care in priority areas for improvement.

  14. The social care guidance manual (PMG10)

    The social care guidance manual

  15. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges (NG11)

    This guideline covers interventions and support for children, young people and adults with a learning disability and behaviour that challenges. It highlights the importance of understanding the cause of behaviour that challenges, and performing thorough assessments so that steps can be taken to help people change their behaviour and improve their quality of life. The guideline also covers support and intervention for family members or carers.

  16. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  17. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    Medicines optimisation: key therapeutic topics – Integrated process statement

  18. Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

    Key therapeutic topics – Medicines management options for local implementation: Interim process statement

  19. Methods for the development of NICE public health guidance (third edition) (PMG4)

    Methods for the development of NICE public health guidance (third edition)

  20. The NICE public health guidance development process (third edition) (PMG5)

    The NICE public health guidance development process (third edition)

  21. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    Evidence summaries: unlicensed and off-label medicines – Interim process statement